{"id":23932,"date":"2025-01-21T23:20:49","date_gmt":"2025-01-22T04:20:49","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=23932"},"modified":"2026-04-13T22:05:34","modified_gmt":"2026-04-14T02:05:34","slug":"the-role-of-biosimilars-in-reducing-out-of-pocket-costs-for-patients","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/the-role-of-biosimilars-in-reducing-out-of-pocket-costs-for-patients\/","title":{"rendered":"Biosimilars and Out-of-Pocket Costs: The Complete Strategic Guide"},"content":{"rendered":"\n

Executive Summary <\/h2>\n\n\n\n
\"\"<\/figure>\n\n\n\n

Biologics account for roughly 2% of U.S. prescriptions but consumed 38-40% of total pharmaceutical spending in 2023. In the European Union, that figure reached \u20ac87.6 billion, or 40% of all drug spend. The cost concentration is not incidental \u2014 it reflects the structural economics of large-molecule drugs produced from living cells, where manufacturing complexity, regulatory burden, and 12-year U.S. market exclusivity under the Biologics Price Competition and Innovation Act (BPCIA) combine to sustain monopoly pricing long after the science matures.<\/p>\n\n\n\n

Biosimilars are the structural remedy. They introduce price competition where none existed, compress average sales prices (ASP) for both the biosimilar and its reference product, and have generated $36 billion in cumulative U.S. savings since 2015. Generic and biosimilar medicines together saved U.S. patients and payers $445 billion in 2023 alone. That headline figure, however, obscures a more troubling reality: the savings largely accrue at the system level, captured by payers, pharmacy benefit managers (PBMs), and integrated health systems. Individual patients, particularly those in high-deductible health plans or Medicare Part B, still face annual biologic out-of-pocket costs ranging from $3,000 for asthma biologics to $100,000+ for certain oncology indications.<\/p>\n\n\n\n

This pillar page maps the complete biosimilar landscape for pharma IP teams, portfolio managers, R&D leads, and institutional investors. It covers the regulatory science of biosimilarity and biosimilar interchangeability, the IP architecture \u2014 patent thickets, BPCIA ‘patent dance’ litigation, and evergreening tactics \u2014 that determines when biosimilars actually reach patients, the financial incentive misalignments that prevent system savings from flowing to individual cost-sharing, and the policy interventions most likely to close that gap.<\/p>\n\n\n\n

Key Takeaways<\/h3>\n\n\n\n
    \n
  • Biosimilars typically launch at a 15-30% discount to the reference product’s ASP, with outliers as steep as 80-90% (ustekinumab) and 65% (insulin glargine biosimilar Semglee vs. Lantus).<\/li>\n\n\n\n
  • Patent thickets \u2014 not primary composition-of-matter patents \u2014 are now the primary tool for blocking biosimilar entry. AbbVie maintained over 250 patents on adalimumab (Humira) before biosimilar entry.<\/li>\n\n\n\n
  • As of late 2023, only 7 U.S. biosimilars held FDA interchangeability designation, creating a structural barrier to pharmacy-level automatic substitution that the EU eliminated entirely.<\/li>\n\n\n\n
  • Copay accumulator programs, deployed by most major PBMs, prevent manufacturer financial assistance from applying to patient deductibles, directly neutralizing the patient-level savings from lower biosimilar list prices.<\/li>\n\n\n\n
  • The Inflation Reduction Act’s Medicare drug price negotiation provisions have introduced developer uncertainty that could produce a ‘biosimilar void’: projections suggest 90% of biologics losing exclusivity in the near term may lack a biosimilar competitor in development.<\/li>\n<\/ul>\n\n\n\n
    \n\n\n\n

    1. The Financial Toxicity Problem <\/h2>\n\n\n\n

    1.1 Biologic Spending by the Numbers<\/h3>\n\n\n\n

    The term ‘financial toxicity’ entered clinical oncology literature to describe the economic harm \u2014 both objective and psychological \u2014 that high treatment costs inflict on patients. It now applies across every therapeutic category where biologics dominate: rheumatology, gastroenterology, dermatology, endocrinology, neurology, and oncology. The concept is not metaphorical. Patients who cannot afford a biologic often abandon or delay treatment, which produces measurable downstream harm: disease progression, avoidable hospitalizations, and long-term disability.<\/p>\n\n\n\n

    A 2022 survey found one in nine Medicare beneficiaries did not fill a physician-prescribed medication because they could not afford it. That non-adherence rate is not evenly distributed. It concentrates among patients on expensive specialty drugs, particularly biologics. For context: annual biologic out-of-pocket costs average $3,000-$5,000 for asthma and allergy indications, $10,000-$30,000 for most arthritis therapies, and exceed $100,000 for certain oncology regimens. Some rare-disease biologics carry annual list prices exceeding $500,000, with patient cost-sharing structures that expose individuals to five- and six-figure annual expenses even with commercial insurance.<\/p>\n\n\n\n

    The math is direct. Biologics cost so much to develop \u2014 a typical development and approval timeline runs 10+ years at a cost of several billion dollars per approved molecule \u2014 that manufacturers set list prices at levels that generate returns on that investment during the exclusivity window. Patients bear a fraction of that list price through cost-sharing structures, but at biologic price points, even a 20% coinsurance rate produces catastrophic individual exposure.<\/p>\n\n\n\n

    1.2 The Non-Adherence Cascade<\/h3>\n\n\n\n

    Non-adherence to biologic therapy is not simply a patient compliance issue. It is a rational economic response to unaffordable out-of-pocket costs, and it carries systemic consequences. Patients who discontinue adalimumab for rheumatoid arthritis experience measurable joint damage acceleration. Patients who abandon trastuzumab mid-cycle face worse breast cancer outcomes. Patients who ration insulin face hospitalization risk. In each case, the downstream cost of managing disease progression and acute complications typically exceeds the cost of continuous therapy, creating a perverse economics where the system saves in the short term by making drugs unaffordable but pays more in the long term through higher utilization costs.<\/p>\n\n\n\n

    Biosimilars disrupt this cascade by reducing the list price foundation from which patient cost-sharing is calculated. That is the core mechanism. But as the sections below detail, the mechanism is blocked at multiple points by regulatory architecture, IP strategy, and financial incentive structures that require explicit policy intervention to fix.<\/p>\n\n\n\n

    \n\n\n\n

    2. What Biosimilars Actually Are \u2014 and What They Are Not <\/h2>\n\n\n\n

    2.1 The Technical Definition<\/h3>\n\n\n\n

    A biosimilar is a biological product demonstrated to be ‘highly similar’ to an FDA- or EMA-approved reference biologic, with no clinically meaningful differences in safety, purity, or potency. The FDA’s standard under the BPCIA requires manufacturers to show biosimilarity through a ‘totality of evidence’ approach: extensive analytical characterization comparing the biosimilar’s physicochemical and functional properties to the reference, followed by pharmacokinetic and pharmacodynamic studies, and, where analytical and clinical pharmacology data leave residual uncertainty, comparative efficacy or safety trials.<\/p>\n\n\n\n

    The key phrase is ‘highly similar,’ not ‘identical.’ Biologics are large, complex molecules \u2014 monoclonal antibodies, for example, have molecular weights 200-1,000 times those of small-molecule drugs \u2014 produced through cell culture processes where natural batch-to-batch variation is inherent. Two lots of the originator biologic are not strictly identical to each other. A biosimilar operates within the same envelope of acceptable variability. The FDA’s requirement, therefore, is not chemical identity (as with generic drugs) but clinical equivalence within a scientifically defined similarity range.<\/p>\n\n\n\n

    2.2 Biosimilars vs. Generics: The Structural Difference<\/h3>\n\n\n\n

    Generic drugs are small molecules. They are chemically synthesized, their structure is fully characterizable by analytical methods, and a generic manufacturer can prove identity with the reference listed drug (RLD) through bioequivalence studies: typically a pharmacokinetic trial in healthy volunteers demonstrating that the generic’s absorption profile falls within 80-125% of the RLD’s. The FDA approves generic drugs through the Abbreviated New Drug Application (ANDA) pathway established by the Hatch-Waxman Act.<\/p>\n\n\n\n

    Biosimilars cannot go through ANDA. Their complexity \u2014 post-translational modifications, glycosylation patterns, protein folding \u2014 means that no analytical package alone can fully characterize biological activity. The 351(k) pathway under the BPCIA requires a more extensive, graduated evidence package. Development cost for a biosimilar typically runs $100-$300 million, compared to $1-$5 million for a typical small-molecule generic. That cost differential explains why the biosimilar market is far less crowded than the generic market, and why therapeutic areas with lower expected market share may produce zero biosimilar entrants even years after reference product patent expiry.<\/p>\n\n\n\n

    2.3 Biosimilarity Is Not Interchangeability<\/h3>\n\n\n\n

    In the U.S., these are distinct regulatory designations with distinct market consequences. Biosimilarity is the base requirement for 351(k) approval. Biosimilar interchangeability is an additional FDA designation \u2014 technically ‘interchangeable biosimilar’ \u2014 that allows pharmacists to substitute the biosimilar for the reference product without intervention by the prescribing physician, in states whose pharmacy laws permit such substitution.<\/p>\n\n\n\n

    To obtain the interchangeability designation, a manufacturer must provide additional data \u2014 typically switching studies in which patients alternate between the reference product and the biosimilar multiple times \u2014 demonstrating that the risk of switching does not exceed the risk of remaining on the reference product. As of late 2023, only 7 biosimilars had received this designation in the U.S. The market consequence is significant: without it, biosimilar substitution requires prescriber involvement, adding administrative friction that slows adoption and sustains reference product market share.<\/p>\n\n\n\n

    The EU reached a different conclusion. The EMA and the Heads of Medicines Agencies issued a joint statement affirming that all EU-approved biosimilars are scientifically interchangeable with their reference products. This harmonized position removes the two-tier designation system entirely, enabling prescribers and pharmacists across member states to treat biosimilars as substitutable without additional regulatory action. The EU approach has contributed to faster biosimilar uptake in several markets, particularly in immunology and oncology.<\/p>\n\n\n\n

    \n\n\n\n

    3. Regulatory Architecture: FDA vs. EMA and the Interchangeability Gap <\/h2>\n\n\n\n

    3.1 The FDA’s 351(k) Pathway in Detail<\/h3>\n\n\n\n

    The Biologics Price Competition and Innovation Act of 2010 created the U.S. abbreviated biosimilar pathway. It established a 12-year data exclusivity period for reference biologics \u2014 separate from, and additive to, patent protection \u2014 during which no biosimilar relying on the reference product’s safety and efficacy data can be approved. After that 12-year window, a biosimilar applicant files a 351(k) BLA, initiating a structured comparison process.<\/p>\n\n\n\n

    FDA review of a 351(k) application typically involves three stages. First, the agency evaluates the analytical data package comparing the biosimilar’s structure, function, and stability to the reference product. Depending on analytical findings, the FDA may request additional studies. Second, clinical pharmacology studies \u2014 generally pharmacokinetic and pharmacodynamic assessments \u2014 are conducted in an appropriate patient population. Third, if the earlier data leave residual uncertainty about clinically meaningful differences, the FDA may require a comparative clinical trial, though the agency has moved toward accepting analytical and clinical pharmacology data as sufficient for many molecules.<\/p>\n\n\n\n

    FDA’s totality-of-evidence standard is science-based and flexible. It reduces development burden for molecules that can be fully characterized analytically \u2014 broadly, the more the molecule behaves like a well-understood antibody with simple effector function, the thinner the clinical evidence package needed. More complex molecules (e.g., those with multiple mechanisms of action, or fusion proteins with novel binding geometries) require more extensive comparative clinical data.<\/p>\n\n\n\n

    3.2 EMA’s Framework and Its Divergence from U.S. Practice<\/h3>\n\n\n\n

    The EMA approved its first biosimilar in 2006, nine years before the FDA. That head start has produced a more mature regulatory science framework and a body of real-world evidence supporting biosimilar interchangeability across multiple therapeutic areas. The EMA’s guidelines require the same core elements \u2014 analytical characterization, pharmacokinetic and pharmacodynamic studies, and, where residual uncertainty exists, comparative clinical data \u2014 but the EMA has been more willing to accept single clinical studies rather than requiring switching study designs for the base biosimilarity determination.<\/p>\n\n\n\n

    The interchangeability position is the most consequential divergence. The EMA-HMA joint statement treats all approved biosimilars as interchangeable for the purpose of prescribing decisions. This is not a permissive stance taken without scientific basis \u2014 it reflects the accumulated body of real-world switching data from EU markets, where national health systems have been conducting non-medical switches (switching stable patients from reference biologics to biosimilars for economic reasons) for years, with no signal of increased adverse events or loss of efficacy in therapeutic drug monitoring data.<\/p>\n\n\n\n

    Several EU member states \u2014 Norway, Denmark, Finland, and the Netherlands prominently \u2014 have run formal non-medical switching programs with monitoring protocols robust enough to generate peer-reviewed outcomes data. That evidence base now spans hundreds of thousands of patient-years of post-switch observation across infliximab, etanercept, adalimumab, rituximab, and trastuzumab biosimilars. The outcomes are consistent: switching between biosimilar and reference does not produce detectable clinical differences in efficacy or safety at the population level.<\/p>\n\n\n\n

    3.3 Extrapolation of Indications<\/h3>\n\n\n\n

    One of the more technically contentious aspects of biosimilar approval \u2014 and one that generates persistent prescriber hesitancy \u2014 is indication extrapolation. When a biosimilar is approved based on clinical data in one indication (e.g., rheumatoid arthritis), the FDA and EMA may approve it for additional indications held by the reference product (e.g., Crohn’s disease, psoriatic arthritis) without requiring clinical data in each. The scientific justification is that if the biosimilar’s mechanism of action is the same as the reference’s, and the structural and pharmacological comparability has been established, the clinical outcomes in indications beyond the studied one will be equivalent.<\/p>\n\n\n\n

    Critics \u2014 primarily originator manufacturers and some specialist societies \u2014 argue that mechanism-based extrapolation is insufficiently validated for indications with distinct pathophysiology. The regulatory agencies have consistently rejected this argument for the currently approved biosimilar classes, where the mechanism is well-characterized. The debate has more merit for highly complex molecules where mechanism is partially understood, such as some immunomodulatory biologics with pleiotropic effects.<\/p>\n\n\n\n

    For biosimilar developers, extrapolation is a core value driver. A biosimilar approved for the full indication set of its reference product can compete across the entire reference product’s revenue base. Narrow indication approval \u2014 which can result from insufficient analytical characterization or specific regulatory concern \u2014 limits the addressable market and undermines the ROI calculation.<\/p>\n\n\n\n

    \n\n\n\n

    4. IP Valuation: The Patent Estates That Block Competition <\/h2>\n\n\n\n

    4.1 The Structure of Biologic IP Protection<\/h3>\n\n\n\n

    For pharma IP teams and institutional investors, understanding the intellectual property architecture around a reference biologic is essential to accurately modeling biosimilar entry timing \u2014 which is, in turn, the primary variable in forecasting reference product revenue decline.<\/p>\n\n\n\n

    Biologic IP protection operates on two independent axes: regulatory exclusivity and patent protection. Regulatory exclusivity under the BPCIA runs for 12 years from the reference product’s approval date and is non-negotiable \u2014 no patent challenge, PTAB proceeding, or litigation outcome can accelerate biosimilar entry during this window. Patent protection, by contrast, is challengeable, and biosimilar manufacturers can and do challenge weak or invalid patents through the BPCIA’s patent dance mechanism, inter partes review (IPR) at the Patent Trial and Appeal Board, or district court litigation.<\/p>\n\n\n\n

    The primary composition-of-matter (CoM) patents on biologics \u2014 covering the sequence or structure of the molecule itself \u2014 typically expire 20 years from filing. For biologics filed in the 1990s and early 2000s, these CoM patents have largely expired. What sustains exclusivity is the secondary patent estate: formulation patents (covering excipient compositions, pH, concentration ranges), method-of-treatment patents (covering dosing regimens, patient selection criteria, combination therapies), manufacturing process patents (covering cell culture conditions, purification steps, bioreactor parameters), device patents (covering delivery systems, prefilled syringes, auto-injectors), and use patents (covering specific disease subtypes or biomarker-defined populations).<\/p>\n\n\n\n

    4.2 AbbVie’s Humira (Adalimumab): The Canonical Patent Thicket Case Study<\/h3>\n\n\n\n

    No case better illustrates the IP strategies deployed by reference product manufacturers than AbbVie’s protection of adalimumab (Humira), the anti-TNF monoclonal antibody that held the title of world’s best-selling drug for multiple consecutive years. Humira’s primary composition-of-matter patent expired in 2016 in the U.S. Biosimilar competitors \u2014 Amgen (Amjevita), Sandoz (Hyrimoz), Boehringer Ingelheim (Cyltezo), Coherus (Yusimry), and several others \u2014 filed 351(k) BLAs and received FDA approval beginning in 2016. Yet none of them launched in the U.S. until January 2023.<\/p>\n\n\n\n

    The 7-year delay had nothing to do with clinical or regulatory deficiencies. AbbVie had built a secondary patent estate of more than 250 patents on Humira’s formulations, methods of use, manufacturing processes, and device configurations. Even if a biosimilar manufacturer invalidated or designed around some of these patents, the litigation risk, cost, and time burden of clearing the full estate made pre-2023 U.S. launch commercially inviable for most challengers. AbbVie settled separately with each biosimilar manufacturer, granting licenses that permitted U.S. market entry from January 2023 onward. This approach \u2014 building a patent thicket large enough to force settlements on the originator’s terms, determining launch timing \u2014 is now a standard reference in biologic life cycle management strategy.<\/p>\n\n\n\n

    The IP valuation implication for analysts: Humira’s U.S. net revenues remained near $14 billion annually through 2022, partially because no biosimilar competition existed in the U.S. market. Post-2023, biosimilar adalimumab has driven significant ASP compression. Early biosimilar entrants launched at approximately 5-14% discounts to Humira’s 2020 net price (reflecting the high-rebate environment PBMs maintained for Humira), but subsequent entrants have driven deeper discounts, and the market is moving toward greater biosimilar share. For AbbVie’s portfolio valuation, the post-2023 trajectory of adalimumab revenue is the single most important variable, and it depends on PBM formulary decisions driven largely by rebate negotiations.<\/p>\n\n\n\n

    IP Valuation Note for Investors: For biosimilar developers, the total addressable IP risk on a target molecule can be quantified by mapping the complete secondary patent estate \u2014 using tools such as the DrugPatentWatch patent database \u2014 and estimating the probability and cost of litigation or design-around for each cluster. The residual IP risk, discounted by probability and time, is the primary haircut applied to biosimilar NPV projections at the development stage.<\/p>\n\n\n\n

    4.3 The BPCIA ‘Patent Dance’: Mechanism and Strategic Implications<\/h3>\n\n\n\n

    The BPCIA’s patent resolution framework \u2014 Section 262 of the Public Health Service Act \u2014 establishes a structured information exchange between the biosimilar applicant (the ‘subsection (k) applicant’) and the reference product sponsor. Upon FDA acceptance of a 351(k) BLA, the biosimilar applicant provides the sponsor with a copy of the BLA and all related manufacturing information. The sponsor then has 60 days to identify patents it believes could be asserted against the biosimilar, and the parties negotiate which patents to include in immediate litigation. A second list of patents can be asserted after the FDA grants approval, but the sponsor cannot seek a preliminary injunction on patents from the second list.<\/p>\n\n\n\n

    Participation in the patent dance is technically optional for the biosimilar applicant, but non-participation triggers separate legal consequences. The Supreme Court addressed this in Sandoz v. Amgen (2017), confirming that refusal to participate does not result in automatic injunctive relief for the originator, but does expose the biosimilar developer to litigation on the originator’s terms rather than the structured exchange framework.<\/p>\n\n\n\n

    From a strategic standpoint, the patent dance creates information asymmetry. The biosimilar applicant must disclose its manufacturing process \u2014 trade secret information \u2014 to the originator sponsor. While the BPCIA contains confidentiality provisions, originator manufacturers gain detailed insight into biosimilar production that they would not otherwise have, which can inform product improvement decisions or IPR challenge strategies. Biosimilar developers must weigh this disclosure cost against the benefits of the structured litigation framework.<\/p>\n\n\n\n

    For IP teams at originator companies, the patent dance presents an opportunity to assert the maximum number of patents in the initial list, creating litigation complexity that increases the cost and duration of any challenge. The eventual settlement \u2014 which is nearly always the outcome for high-value molecules \u2014 then reflects the leverage the originator’s patent estate creates. For biosimilar developers, the strategic counter is aggressive IPR petitioning at the PTAB for weak secondary patents, reducing the estate size before or during litigation.<\/p>\n\n\n\n

    4.4 Evergreening Tactics Specific to Biologics<\/h3>\n\n\n\n

    Evergreening \u2014 the use of secondary patents to extend effective market exclusivity beyond the primary patent term \u2014 takes several forms in biologics that differ from small-molecule drugs.<\/p>\n\n\n\n

    Device and delivery system patents are particularly potent in biologics because most are administered via injection or infusion, and the delivery device is often integral to patient acceptance and adherence. A biosimilar developer who produces an equivalent molecule but cannot access the auto-injector design used by the reference product must either design a different device (adding development cost and regulatory complexity) or accept that patients familiar with the reference device may resist switching to a device with a different form factor. AbbVie’s Humira pen designs and Amgen’s Enbrel prefilled syringe configurations are both covered by device patents separate from the molecule’s IP.<\/p>\n\n\n\n

    Manufacturing process patents present a related challenge. Because biologic manufacturing is inherently process-dependent \u2014 the product is the process, in regulatory terms \u2014 even a biosimilar with identical primary sequence may have difficulty demonstrating analytical comparability if its manufacturing process produces a different glycoform profile. Originator patents on specific upstream process parameters (cell culture media compositions, temperature profiles, pH ranges) or downstream purification steps can force biosimilar developers to use less-optimized processes, increasing COGS and reducing competitive margin.<\/p>\n\n\n\n

    Formulation patents covering stabilizer concentrations, pH ranges, or preservative compositions are typically the weakest secondary patents from a validity standpoint \u2014 the inventive step is thin \u2014 but require resources to challenge. PTAB IPR success rates for formulation patents are generally higher than for method-of-use claims, making them lower-risk targets for biosimilar challengers.<\/p>\n\n\n\n

    Key Takeaways: IP Valuation<\/h3>\n\n\n\n
      \n
    • For any biologic target, map secondary patents by cluster type (formulation, device, manufacturing, method-of-use) and estimate litigation or design-around cost per cluster before projecting entry timing.<\/li>\n\n\n\n
    • PTAB IPR is the most efficient vehicle for invalidating weak secondary patents before FDA approval, because it avoids the information disclosure requirements of the patent dance and can run in parallel with BLA review.<\/li>\n\n\n\n
    • Settlement timing is a function of originator leverage (estate size and quality) and biosimilar developer capital position. Well-capitalized developers (Amgen, Samsung Bioepis, Sandoz) extract earlier settlements. Smaller developers may be forced into longer litigation or licensing terms that impair their competitive economics.<\/li>\n\n\n\n
    • AbbVie post-Humira has concentrated its next-generation pipeline in immunology molecules \u2014 risankizumab (Skyrizi) and upadacitinib (Rinvoq) \u2014 that have smaller secondary patent estates relative to Humira, though both benefit from method-of-use patent protection.<\/li>\n<\/ul>\n\n\n\n
      \n\n\n\n

      5. Mechanisms of Cost Reduction <\/h2>\n\n\n\n

      5.1 Competition as the Primary Price Driver<\/h3>\n\n\n\n

      The most reliable mechanism by which biosimilars reduce drug prices is market competition. When multiple biosimilar manufacturers enter a market, they compete on price for formulary placement, hospital contract awards, and integrated delivery network (IDN) preferred product status. This competition compresses ASP across all products in the class, including the reference biologic.<\/p>\n\n\n\n

      Analysis of U.S. biosimilar markets shows that single-entry biosimilar markets produce modest price reductions \u2014 typically 15-25% below reference product ASP. Multi-entry markets produce far steeper compression. In the filgrastim market, where multiple biosimilars have competed since 2018, WAC reductions exceeded 55% from reference product levels, and ASP compression has been even greater due to competitive bidding for hospital contracts. The insulin glargine market, following Semglee’s launch at a 65% list price discount to Lantus, is now tracking toward a similar multi-entrant dynamic.<\/p>\n\n\n\n

      The implication for cost reduction at the patient level is sequential. First, lower reference product ASP reduces the absolute dollar amount of percentage-based coinsurance, even if the patient remains on the reference product. Second, if the patient switches to the biosimilar, the lower biosimilar list price \u2014 where it translates to a lower formulary tier \u2014 reduces the fixed-dollar copay. Third, if biosimilar competition is sufficient to drive reference product repricing, the net savings compound across all cost-sharing structures in the patient population.<\/p>\n\n\n\n

      5.2 ASP-Plus-6 and the Part B Incentive Problem<\/h3>\n\n\n\n

      Medicare Part B covers drugs administered in a clinical setting \u2014 infusions, injections administered by a healthcare professional \u2014 under a reimbursement model that pays providers ASP plus 6% of ASP as a handling and administration add-on. This model contains a structural incentive that works against biosimilar adoption.<\/p>\n\n\n\n

      The absolute dollar value of the 6% add-on is higher for a more expensive drug. A provider administering a biologic with a $5,000 ASP receives $300 in the add-on. The same provider administering a biosimilar at $3,000 ASP receives $180. The provider’s drug-related margin is $120 higher per administration for the more expensive product, despite identical clinical work. This incentive does not necessarily drive prescribing decisions for ethical practitioners, but at the margin \u2014 particularly for practices with thin revenue \u2014 it slows biosimilar adoption.<\/p>\n\n\n\n

      The BIOSIM Act, introduced in Congress, would address this by setting the Medicare add-on for biosimilars at 8% rather than 6%, closing part of the financial gap. The CMS has also experimented with the Oncology Care Model and other value-based payment constructs that remove per-drug margin incentives, but these programs have not achieved broad adoption. Until the ASP-plus-6 structure is modified, providers in Part B settings face a financial disincentive to adopt biosimilars, and the patient cost-sharing benefits of biosimilar competition are partially offset.<\/p>\n\n\n\n

      5.3 WAC, ASP, and Net Price: The Three-Layer Pricing Reality<\/h3>\n\n\n\n

      Understanding how biosimilar pricing flows through the supply chain requires distinguishing three distinct price points.<\/p>\n\n\n\n

      Wholesale acquisition cost (WAC) is the manufacturer’s list price charged to wholesalers, before rebates or discounts. WAC is what appears on published price lists and drives some patient cost-sharing calculations, particularly for drugs purchased at retail pharmacies. Average sales price (ASP) is WAC minus all rebates and discounts, averaged across all purchasers over the prior quarter, reported to CMS quarterly. ASP is the basis for Medicare Part B reimbursement. Net price is what the manufacturer actually receives after all rebates, chargebacks, and discounts \u2014 the closest measure of realized revenue.<\/p>\n\n\n\n

      For biosimilars, the spread between WAC and net price can be enormous. In the adalimumab market, originator Humira maintained high WAC while offering large rebates to PBMs for preferred formulary status. Early adalimumab biosimilars launched at WAC discounts of 5-14% to Humira’s WAC, which looked modest, but the net price dynamics were complex \u2014 PBMs receiving high Humira rebates had little incentive to switch to biosimilars unless the biosimilar’s net price (after any biosimilar rebates) was lower than Humira’s net price after rebates.<\/p>\n\n\n\n

      For patients, the price layer that matters depends on their benefit design. Patients with coinsurance calculated on list price (common in some commercial plans) benefit most from WAC reductions. Patients with fixed-dollar copays keyed to formulary tiers benefit from formulary tier placement, which is a function of net price and PBM negotiation outcomes. The practical implication: a biosimilar launching at a steep WAC discount does not automatically translate to patient cost-sharing reduction if PBM formulary decisions keep the reference product preferred.<\/p>\n\n\n\n

      \n\n\n\n

      6. PBM Formulary Power and the Rebate Trap <\/h2>\n\n\n\n

      6.1 PBM Market Structure<\/h3>\n\n\n\n

      Three PBMs \u2014 CVS Caremark, Express Scripts (Evernorth), and OptumRx \u2014 collectively process the majority of U.S. commercial prescription drug claims. Their formulary decisions determine, for most commercially insured patients, which drugs are covered, at what cost-sharing tier, and with what prior authorization requirements. This market concentration gives PBMs extraordinary leverage in negotiations with both originator manufacturers and biosimilar developers.<\/p>\n\n\n\n

      PBMs generate revenue through several mechanisms: administrative fees charged to plan sponsors, spread pricing (the difference between what they charge the plan and what they pay the pharmacy), and rebates negotiated with manufacturers in exchange for formulary placement. The rebate mechanism is the primary source of tension in the biosimilar context. Originator manufacturers, seeking to protect their products from biosimilar displacement, offer substantial rebates to PBMs in exchange for preferred tier status or exclusion of biosimilar alternatives. These rebates can be large enough that the net cost to the plan of the reference product is lower than the net cost of the biosimilar, despite the biosimilar having a lower list price \u2014 a dynamic that directly contradicts patient and policymaker intuition.<\/p>\n\n\n\n

      6.2 CVS Caremark’s Formulary Exclusion Strategy<\/h3>\n\n\n\n

      CVS Caremark’s 2023 decision to exclude reference adalimumab from its national commercial template formulary, driving 97% of prescriptions to preferred biosimilars, demonstrates the speed and magnitude of PBM-driven market shifts. That formulary decision did not come because biosimilar adalimumab had superior clinical evidence. It came because CVS Caremark calculated that biosimilar net prices \u2014 after biosimilar manufacturer incentives designed to compete with Humira rebates \u2014 were lower than Humira’s net price, and because the regulatory interchangeability question was moot in this case (rheumatologists were already writing prescriptions specifying biosimilars by name).<\/p>\n\n\n\n

      For biosimilar developers, securing PBM formulary placement is as critical as FDA approval. A biosimilar with BLA in hand but no PBM formulary access faces significant penetration barriers, particularly for drugs administered in the outpatient pharmacy channel. The negotiating dynamic requires biosimilar manufacturers to offer either lower net prices (competing on price) or clinical differentiation arguments (usually unavailable, given that biosimilarity means no clinically meaningful differences) or device\/service advantages (which can marginally support formulary preference in some negotiations).<\/p>\n\n\n\n

      6.3 The Copay Accumulator Problem<\/h3>\n\n\n\n

      Copay accumulator adjustment programs (CAAPs) are PBM mechanisms that prevent manufacturer-provided patient copay assistance \u2014 typically offered through manufacturer copay cards or patient assistance programs \u2014 from counting toward a patient’s annual deductible or out-of-pocket maximum. The structure works as follows: a patient receives a copay card from the manufacturer covering their out-of-pocket cost for a drug. Under a standard benefit design, each copay payment would count toward the patient’s annual deductible. Under a CAAP, those payments are excluded, so the patient’s deductible resets at the end of the copay assistance limit, exposing them to full cost-sharing for the remainder of the plan year.<\/p>\n\n\n\n

      CAAPs were designed to prevent manufacturers from using copay assistance to effectively subsidize patient access to high-list-price drugs while blocking formulary migration to generics or biosimilars. The intent had merit. But in practice, CAAPs also prevent copay assistance for biosimilars from reducing patient financial burden, even when the biosimilar is the formulary-preferred product. Patients receiving biosimilar manufacturer copay assistance face the same accumulator problem as patients receiving originator manufacturer assistance.<\/p>\n\n\n\n

      As of 2025, 25 states, the District of Columbia, and Puerto Rico have enacted legislation banning CAAPs or requiring that copay assistance count toward cost-sharing obligations. Federal legislation to address CAAPs has been introduced but not enacted. Until this changes, CAAPs represent a direct policy mechanism by which the patient-level financial benefit of biosimilar adoption is extracted from patients and retained by payers.<\/p>\n\n\n\n

      \n\n\n\n

      7. Real-World Savings: Oncology, Immunology, Diabetes, Supportive Care <\/h2>\n\n\n\n

      7.1 System-Level Savings Context<\/h3>\n\n\n\n

      Generic and biosimilar medicines filled approximately 90% of U.S. prescription volume in 2023 while accounting for only 13-17.5% of total prescription drug spending. This inversion \u2014 high volume, low spend share \u2014 is the core economic contribution of competition to pharmaceutical affordability. Without biosimilars, the 38-40% biologic share of total drug spend would be substantially higher, as originator prices would face no competitive pressure.<\/p>\n\n\n\n

      Since biosimilar entry began in 2015, the cumulative U.S. savings figure reached $36 billion through 2023. Biosimilars had also supported 495 million incremental days of therapy by 2023, representing care that patients received who might not have received it at reference product prices. These are population-level metrics. The section below disaggregates them by therapeutic area, where the patient-level savings dynamics differ substantially.<\/p>\n\n\n\n

      7.2 Oncology Biosimilars<\/h3>\n\n\n\n

      Oncology biologics \u2014 trastuzumab, bevacizumab, rituximab, filgrastim, pegfilgrastim, epoetin alfa \u2014 were among the first targets for biosimilar development, and the savings have been substantial. In 2021, oncology biosimilar use generated over $17 billion in savings. By 2023, the latest wave of oncology biosimilars contributed more than $2.4 billion in savings across cancers of the brain, breast, cervix, colon, kidney, lung, and stomach, as well as leukemia and non-Hodgkin lymphoma. Biosimilar competition cut oncology spending growth in half since 2019.<\/p>\n\n\n\n

      Specific ASP trajectories illustrate the mechanism. Trastuzumab biosimilars \u2014 Herzuma (Celltrion), Kanjinti (Amgen), Ogivri (Mylan\/Biocon) \u2014 entered a market where reference trastuzumab (Herceptin) carried an ASP that drove meaningful patient cost-sharing even with commercial insurance. Within three years of biosimilar entry, trastuzumab ASPs fell by up to 82%. For a breast cancer patient with 20% coinsurance on a Part B drug, an 82% reduction in ASP translates to an 82% reduction in their coinsurance payment. That is not a theoretical saving. It is a direct, calculable reduction in per-infusion financial toxicity.<\/p>\n\n\n\n

      Bevacizumab (Avastin) biosimilars followed a similar trajectory, though the market dynamics were complicated by the simultaneous launch of bevacizumab in ophthalmology (where off-label use of the oncology product is common) and competition from ranibizumab biosimilars. The net effect across the bevacizumab market has been sustained downward pressure on ASP, with patient-level benefits accruing primarily in the Part B setting where coinsurance is calculated on ASP.<\/p>\n\n\n\n

      Pembrolizumab (Keytruda) and atezolizumab biosimilars are on the development horizon, with first entries projected in the late 2020s following primary patent expirations. Given Keytruda’s status as the current global revenue leader among biologics \u2014 with annual sales exceeding $25 billion \u2014 the biosimilar entry event for pembrolizumab will represent one of the largest single patent cliff events in pharmaceutical history.<\/p>\n\n\n\n

      7.3 Immunology: The Adalimumab and Infliximab Markets<\/h3>\n\n\n\n

      Adalimumab (Humira) and infliximab (Remicade) are the foundational cases for understanding biosimilar dynamics in immunology, and they tell different stories.<\/p>\n\n\n\n

      Infliximab biosimilars \u2014 Inflectra (Celltrion\/Pfizer) and Renflexis (Samsung Bioepis\/Organon), among others \u2014 entered the U.S. market in 2016 and the EU market in 2015. In Canada, infliximab biosimilar adoption reduced costs by approximately 50% compared to reference Remicade. In Norway, the national tendering system drove infliximab biosimilar penetration above 90%, with post-switch monitoring data showing no difference in clinical outcomes. The Norwegian experience has become the empirical reference for policymakers assessing mandatory non-medical switching programs.<\/p>\n\n\n\n

      In the U.S., infliximab biosimilar uptake was slower due to the rebate dynamics described above. J&J, marketing Remicade through Janssen, used aggressive rebate contracts to maintain formulary preferred status in many commercial plans, limiting biosimilar penetration for years after FDA approval. This dynamic changed as PBMs recalculated net price comparisons and several IDNs shifted purchasing to biosimilars for their hospital formularies.<\/p>\n\n\n\n

      The adalimumab market is more complex. U.S. biosimilar entry began in January 2023, with multiple manufacturers launching simultaneously. The PBM response was not uniform. Some \u2014 CVS Caremark most aggressively \u2014 excluded reference Humira from preferred formulary status. Others maintained reference Humira at preferred status through 2023, sustained by AbbVie’s rebate commitment. The market has been bifurcating: high-rebate\/high-list originator channel for plans where AbbVie’s rebate math still works, and biosimilar-preferred channel for plans where PBM net price calculations favor biosimilars. The long-term trajectory clearly favors biosimilar share growth, but the pace depends on continued PBM formulary action and prescriber conversion rates.<\/p>\n\n\n\n

      IP Valuation Note: AbbVie’s patent estate defense of adalimumab generated roughly $70 billion in U.S. revenues between 2016 and 2022 that might have faced biosimilar competition had the patent thicket strategy failed. For portfolio managers tracking AbbVie, the central question for 2024-2027 is the pace of adalimumab revenue decline and whether Skyrizi and Rinvoq can absorb that volume. AbbVie’s guidance through 2023 suggested Skyrizi\/Rinvoq combined revenue growth can offset Humira decline by 2025, but the trajectory depends on their own patent life cycles \u2014 both are protected through the early 2030s by primary patents.<\/p>\n\n\n\n

      7.4 Diabetes: Biosimilar Insulin<\/h3>\n\n\n\n

      Insulin occupies a unique regulatory position. Historically classified as a drug rather than a biologic in the U.S., insulin products were initially approved through the NDA pathway rather than BLA. A regulatory transition completed in March 2020 reclassified all insulin products as biologics under the BPCIA framework, enabling the 351(k) biosimilar pathway.<\/p>\n\n\n\n

      Semglee (insulin glargine-yfgn, Viatris\/Biocon) was approved as both an interchangeable biosimilar to Lantus in July 2021 and holds the distinction of being among the earliest interchangeable biosimilar designations in the U.S. It launched at a 65% discount to Lantus’s list price. Subsequent interchangeable biosimilar insulin products have entered the market, and analysts project that sustained multi-entrant competition in the biosimilar insulin market could reduce annual insulin costs to $130 or below.<\/p>\n\n\n\n

      The insulin case is particularly high-stakes from a patient access standpoint. Patients who ration insulin \u2014 a documented behavior in the U.S. driven by unaffordable out-of-pocket costs \u2014 face life-threatening consequences. The biosimilar insulin market, combined with insulin manufacturer voluntary price reductions and the IRA’s $35 monthly cap on Medicare insulin cost-sharing, has materially improved affordability for Medicare beneficiaries. Commercial patient access remains more variable, dependent on plan design and formulary placement.<\/p>\n\n\n\n

      7.5 Supportive Care Biosimilars<\/h3>\n\n\n\n

      Supportive care biosimilars \u2014 particularly in oncology, where filgrastim, pegfilgrastim, and epoetin alfa are used to manage chemotherapy-induced neutropenia and anemia \u2014 have achieved the highest biosimilar penetration rates of any therapeutic category in the U.S., reflecting the hospital formulary environment where purchasing decisions are centralized and made by pharmacy and therapeutics committees rather than individual prescribers.<\/p>\n\n\n\n

      Biosimilar adoption rates for supportive care: filgrastim biosimilars reached 84.8% penetration; epoetin alfa biosimilars reached 76.2%; pegfilgrastim biosimilars reached 52.6%. WAC reductions in this category ranged from 35-55% below reference product levels. The lower pegfilgrastim penetration rate reflects the complexity of that molecule and the mix of provider setting types \u2014 oncology infusion centers vary more in their formulary management than hospital inpatient settings.<\/p>\n\n\n\n

      \n\n\n\n

      8. The Adoption Gap: Why Savings Don’t Reach Patients <\/h2>\n\n\n\n

      8.1 The Nocebo Effect and Prescriber Hesitancy<\/h3>\n\n\n\n

      Multiple survey datasets establish that prescriber confidence in biosimilars \u2014 while improving \u2014 remains the primary behavioral barrier to adoption in therapeutic areas outside supportive care. Physicians who treat patients stabilized on a reference biologic are reluctant to initiate non-medical switching, not because the clinical evidence supports that reluctance but because the nocebo effect \u2014 where negative patient expectations produce perceived negative clinical outcomes \u2014 is a real and documented phenomenon in biosimilar switching studies.<\/p>\n\n\n\n

      Switching studies in inflammatory bowel disease have shown that IBD patients switched from reference infliximab to biosimilar infliximab experienced higher rates of subjective symptom worsening than patients who continued on the reference product, despite identical objective disease markers (fecal calprotectin, endoscopy scores). This nocebo-driven subjective worsening does not reflect true drug failure but does drive prescribers to revert to the reference product, undermining cost-saving efforts.<\/p>\n\n\n\n

      Managing the nocebo effect requires active patient education, not passive information provision. Practices that brief patients on what biosimilars are, why they are clinically equivalent, and what to expect during a switch \u2014 before initiating the switch \u2014 show substantially lower rates of nocebo-related reversion. This is documented in the Danish and Norwegian infliximab switching programs, which embedded pre-switch counseling into standard protocol and achieved persistent high adherence rates post-switch.<\/p>\n\n\n\n

      8.2 Misaligned Financial Incentives: A Complete Map<\/h3>\n\n\n\n

      The U.S. healthcare system contains at least four distinct incentive misalignments that suppress biosimilar adoption at the prescriber and payer level.<\/p>\n\n\n\n

      The Part B ASP-plus-6 problem is described above. The PBM rebate problem \u2014 where originator rebates make reference products net-price competitive despite higher list prices \u2014 is also described above. Two additional misalignments deserve attention.<\/p>\n\n\n\n

      Specialty pharmacy channel capture is a practice by which originator manufacturers establish preferred specialty pharmacy networks for their biologics, offering patient support services (nurse hotlines, copay assistance, injection training) through those networks. When a PBM or plan attempts to switch patients to biosimilars, the patient’s established relationship with the originator’s specialty pharmacy network creates friction \u2014 patients must reestablish care relationships, and the network has no financial incentive to facilitate the transition. Several originator manufacturers have explicitly used specialty pharmacy channel management as a biosimilar defense tool.<\/p>\n\n\n\n

      Site-of-care economics create a different misalignment in the hospital outpatient department (HOPD) setting. Hospitals bill for outpatient infusions under the Medicare Outpatient Prospective Payment System (OPPS), which reimburses at rates substantially higher than physician office or community oncology clinic rates for the same infusion. Because HOPD reimbursement is less directly tied to ASP in the same way Part B is, the per-drug margin incentive described above is modulated \u2014 but replaced by a broader institutional incentive to maintain high-volume infusion services. Biosimilar adoption in HOPDs has been faster than in physician offices for some molecules (reflecting central P&T committee decisions), slower for others (reflecting revenue cycle considerations).<\/p>\n\n\n\n

      8.3 The Biosimilar Void: IRA Price Negotiation and Development Disincentives<\/h3>\n\n\n\n

      The Inflation Reduction Act’s drug price negotiation provisions, operational for Medicare Part D drugs starting in 2026 and Part B drugs on a later timeline, have introduced a structural disincentive for biosimilar development that deserves close attention from both policy analysts and investors.<\/p>\n\n\n\n

      The IRA allows CMS to negotiate prices for high-expenditure Medicare drugs. For small-molecule drugs, the negotiation ceiling is set at a percentage of non-federal average manufacturer price (non-FAMP) that scales with the drug’s post-approval age. Biologics face a longer time period before becoming eligible for negotiation, reflecting their development cost and complexity. However, the mechanism creates a problem for biosimilar economics: if a reference biologic is subject to Medicare price negotiation, its negotiated price may be low enough that a biosimilar launched at a modest discount to that negotiated price cannot recover development costs.<\/p>\n\n\n\n

      The projected consequence is a ‘biosimilar void’: analysts estimate that up to 90% of biologics scheduled to lose exclusivity in the coming years may lack a biosimilar competitor in development, in part because potential developers cannot construct a viable business case given IRA-driven reference product price uncertainty. This is not a hypothetical concern. Several biosimilar programs targeting high-value biologics have been deprioritized or shelved by mid-tier manufacturers citing IRA market uncertainty.<\/p>\n\n\n\n

      For institutional investors, this is a key monitoring variable. Biosimilar void risk affects both originator manufacturers (whose revenue decline timelines may be extended if biosimilar entry is delayed or absent) and specialty pharma companies whose pipelines depend on biosimilar competition to drive market share.<\/p>\n\n\n\n

      \n\n\n\n

      9. Policy Roadmap: What Needs to Change <\/h2>\n\n\n\n

      9.1 Interchangeability Harmonization<\/h3>\n\n\n\n

      The most operationally direct policy change available is legislative or regulatory harmonization of the biosimilar interchangeability standard with the EU approach. If all FDA-approved biosimilars were treated as interchangeable for pharmacy substitution purposes \u2014 removing the requirement for separate switching studies and the interchangeable biosimilar designation \u2014 pharmacists could substitute biosimilars for reference products in all states with relevant substitution laws, without prescriber intervention.<\/p>\n\n\n\n

      The scientific basis for this is established. Years of EU real-world data, across multiple molecules and patient populations, show no safety or efficacy signal associated with switching. The FDA’s own scientific staff has acknowledged this evidence base. The political barrier is originator industry opposition, which frames the interchangeability standard as a patient safety issue but is more accurately a market protection mechanism. Eliminating the interchangeability designation requirement would accelerate pharmacy-level substitution, compress reference product market share, and deliver the most rapid patient-level cost savings of any single policy intervention.<\/p>\n\n\n\n

      9.2 Patent Thicket Reform<\/h3>\n\n\n\n

      Reforming the secondary patent system as applied to biologics requires a more targeted approach than broad pharmaceutical patent reform. Two mechanisms have the strongest evidence base.<\/p>\n\n\n\n

      First, requiring that patents listed in the FDA’s Purple Book (the biologic equivalent of the Orange Book) meet a heightened relevance standard \u2014 specifically, that they directly claim the approved product or a manufacturing process essential to its production \u2014 would eliminate the practice of listing peripheral patents (device patents, method-of-use patents with thin inventive steps) that create litigation complexity without protecting genuine innovation.<\/p>\n\n\n\n

      Second, giving biosimilar applicants earlier standing to challenge originator patents through IPR \u2014 before they invest in the clinical development program \u2014 would reduce the risk profile of biosimilar development. Currently, a biosimilar developer cannot file a 351(k) BLA (which triggers the patent dance) until it has completed expensive comparability studies. Earlier patent certainty would reduce development-stage investment risk.<\/p>\n\n\n\n

      9.3 CAAP Federal Prohibition<\/h3>\n\n\n\n

      Federal legislation banning copay accumulator adjustment programs, requiring that any manufacturer financial assistance \u2014 for any FDA-approved drug, not just biosimilars \u2014 count toward patient deductibles and out-of-pocket maximums, is the most direct mechanism for ensuring that list price reductions translate to patient-level financial benefit. The state-level patchwork of CAAP laws (25 states, DC, and Puerto Rico as of 2025) creates compliance complexity without uniform patient protection. A federal standard would close the gap.<\/p>\n\n\n\n

      9.4 ASP-Plus-6 Restructuring<\/h3>\n\n\n\n

      Increasing the Medicare Part B add-on payment for biosimilars relative to reference products \u2014 as proposed in the BIOSIM Act at 8% versus 6% \u2014 partially addresses the per-drug margin incentive that slows provider adoption. A more complete solution would cap the dollar value of the add-on payment for reference products at the level that would apply if the product were priced equivalently to its most cost-effective biosimilar competitor, eliminating the financial incentive to prescribe the reference product on pricing grounds.<\/p>\n\n\n\n

      \n\n\n\n

      10. Investment Strategy for Analysts <\/h2>\n\n\n\n

      10.1 Valuing Biosimilar Pipelines<\/h3>\n\n\n\n

      The NPV of a biosimilar program depends on six variables: addressable market size (reference product revenue in target geographies), projected launch timing (a function of IP landscape analysis), expected price discount at launch and competitive equilibrium ASP, market penetration trajectory (driven by formulary access and prescriber conversion), development cost to BLA approval, and manufacturing COGS. Of these, launch timing and market penetration are the highest-uncertainty inputs and deserve scenario analysis rather than point estimates.<\/p>\n\n\n\n

      For launch timing, the key analytical work is IP landscaping: mapping the complete secondary patent estate on the target molecule, assessing PTAB IPR vulnerability for each cluster, modeling litigation duration and settlement probability. Firms that invest in rigorous IP landscaping before committing to biosimilar development have materially better outcomes than those relying on primary patent expiry dates alone.<\/p>\n\n\n\n

      For market penetration, the most reliable predictors are therapeutic area (supportive care > hospital-administered oncology biologics > self-administered immunology biologics in terms of biosimilar adoption speed), payer landscape (PBM formulary inclusion probability), and prescriber concentration (concentrated prescriber bases, such as subspecialty oncologists at academic centers, adopt faster when key opinion leaders are converted). Biosimilars that require prescriber education programs to overcome documented hesitancy (some IBD biologics, certain neurology biologics) should carry lower penetration trajectory assumptions in years 1-3 post-launch.<\/p>\n\n\n\n

      10.2 Originator Company Exposure Assessment<\/h3>\n\n\n\n

      For portfolio managers holding originator biologic manufacturers, the patent cliff analysis requires attention to secondary patent estate durability, not just primary patent expiry. An originator whose secondary estate includes high-quality device patents (with design-around difficulty) and strong formulation patents (with multiple validated IP challenges already defeated) may enjoy 3-5 additional years of effective market exclusivity beyond primary patent expiry. An originator relying primarily on method-of-use patents with thin inventive steps faces faster biosimilar entry.<\/p>\n\n\n\n

      Key molecules on the 2025-2030 patent cliff with active or imminent biosimilar development include ustekinumab (Stelara, J&J), with biosimilars having launched in 2023-2024 in the U.S. at discounts of 80-90%; pembrolizumab (Keytruda, Merck), with primary patent expiry in 2028 and biosimilar programs in early development at multiple manufacturers; and natalizumab (Tysabri, Biogen), where the complex regulatory history of the molecule and REMS program create biosimilar entry barriers beyond the patent landscape.<\/p>\n\n\n\n

      10.3 Monitoring the Biosimilar Void Risk<\/h3>\n\n\n\n

      The potential for IRA-driven reduction in biosimilar development activity is the most significant systemic risk to the long-term biosimilar competitive landscape. Portfolio managers with positions in originator biologics approaching patent expiry should assess whether credible biosimilar programs exist for those molecules, and should not assume that patent expiry automatically produces biosimilar competition. If the biosimilar void concern materializes as projected, several large biologics may face no biosimilar competition for years beyond their primary patent expiry \u2014 an outcome that extends originator revenue timelines but also perpetuates patient financial toxicity.<\/p>\n\n\n\n

      For investors specifically in biosimilar-focused companies (Celltrion, Samsung Bioepis, Sandoz’s standalone biosimilar business, Coherus, Biocon Biologics), the IRA risk is a direct pipeline threat. Companies with clinical-stage programs targeting high-value molecules that are also IRA negotiation candidates should be monitored for pipeline reprioritization announcements. Conversely, companies with biosimilar programs targeting molecules that are not CMS negotiation candidates \u2014 because they lack sufficient Medicare spend to qualify \u2014 may face lower competitive development risk and cleaner market entry assumptions.<\/p>\n\n\n\n

      \n\n\n\n

      11. Actionable Recommendations by Stakeholder <\/h2>\n\n\n\n

      11.1 For Pharma IP Teams at Originator Companies<\/h3>\n\n\n\n

      Map your complete secondary patent estate annually for all marketed biologics, not only those approaching primary patent expiry. Assess PTAB IPR vulnerability for each patent cluster. Identify which patents are genuinely defensible versus those that represent litigation burden rather than IP value. Consider whether your patent thicket strategy, if it mirrors the adalimumab model, is priced into market consensus for your biosimilar entry timeline \u2014 because analysts covering your competitors are doing this work.<\/p>\n\n\n\n

      For life cycle management, device improvement and formulation optimization investments made now can generate patentable innovations that are clinically differentiated, not merely patent-extended. Patients who have adopted a device with genuine usability advantages over the biosimilar alternative will be harder to switch, for legitimate reasons rather than pure inertia.<\/p>\n\n\n\n

      11.2 For Biosimilar Developers<\/h3>\n\n\n\n

      Prioritize interchangeability designation for any self-administered, pharmacy-dispensed biosimilar where the reference product has significant retail channel volume. The regulatory cost of switching studies is recoverable through the formulary access advantages an interchangeable designation provides.<\/p>\n\n\n\n

      Build PBM engagement into your market access strategy at least 18 months before projected launch. Formulary inclusion \u2014 not just FDA approval \u2014 determines launch year market penetration. The manufacturers with the most favorable adalimumab biosimilar formulary outcomes in 2023 had begun PBM negotiation well before BLA approval.<\/p>\n\n\n\n

      Invest in real-world evidence generation from day one of launch. Prescriber hesitancy in therapeutic areas with documented nocebo concern (IBD, dermatology, neurology) responds to accumulating post-marketing data. A robust pharmacovigilance program that generates publishable outcomes data is a marketing asset, not merely a regulatory requirement.<\/p>\n\n\n\n

      11.3 For Payers and PBMs<\/h3>\n\n\n\n

      Formulary design that places biosimilars at preferred tier while maintaining reference product access at higher cost-sharing levels is the most direct mechanism available to payers to reduce patient financial burden without restricting clinical choice. The CVS Caremark adalimumab strategy demonstrated that decisive formulary action drives rapid biosimilar adoption without adverse patient outcomes.<\/p>\n\n\n\n

      Eliminate or suspend CAAP application for biosimilar products. The argument for CAAPs as a cost-containment tool for high-cost originators does not apply to lower-cost biosimilars. Applying accumulators to biosimilar patient assistance programs directly contradicts the stated goal of making care more affordable.<\/p>\n\n\n\n

      11.4 For Healthcare Providers<\/h3>\n\n\n\n

      Standardize pre-switch patient counseling for any planned non-medical switch. The evidence is clear that brief, structured counseling before switching reduces nocebo-driven reversion rates significantly. This is a low-cost intervention with high impact on both patient experience and cost outcomes.<\/p>\n\n\n\n

      Engage your institution’s pharmacy and therapeutics committee in biosimilar formulary policy. The P&T committee is the most efficient leverage point for systemic biosimilar adoption in hospital and health system settings, where individual prescriber decisions can be aligned with institutional formulary management.<\/p>\n\n\n\n

      11.5 For Policymakers<\/h3>\n\n\n\n

      Prioritize federal CAAP prohibition. The state-by-state patchwork creates administrative complexity and leaves patients in non-CAAP states exposed to this direct neutralization of biosimilar savings. This is also politically feasible \u2014 CAAPs lack a natural constituency among patients, providers, or most payers.<\/p>\n\n\n\n

      Commission a structured evidence review of interchangeability harmonization. The EU-U.S. divergence on biosimilar interchangeability is not well-documented in U.S. policy discourse. A systematic review of EU real-world switching data, conducted by an independent body, could accelerate the political case for eliminating the separate interchangeable biosimilar designation or substantially streamlining the evidence requirements.<\/p>\n\n\n\n

      Address the IRA biosimilar void through supplementary guidance that creates clearer exclusions or adjusted negotiation floors for molecules where biosimilar development is active or anticipated. This does not require legislative action \u2014 CMS has interpretive latitude in implementing the negotiation framework that it has not fully exercised.<\/p>\n\n\n\n

      \n\n\n\n

      12. Appendix: Data Tables <\/h2>\n\n\n\n

      Table A: Reference Biologic ASP Trajectories After Biosimilar Entry<\/h3>\n\n\n\n
      Reference Product<\/th>INN<\/th>First U.S. Biosimilar Entry<\/th>ASP Reduction at 3 Years<\/th><\/tr><\/thead>
      Herceptin<\/td>Trastuzumab<\/td>2019<\/td>Up to 82%<\/td><\/tr>
      Remicade<\/td>Infliximab<\/td>2016<\/td>~50% (U.S., multiple entrants)<\/td><\/tr>
      Neupogen<\/td>Filgrastim<\/td>2015<\/td>~55% WAC<\/td><\/tr>
      Neulasta<\/td>Pegfilgrastim<\/td>2018<\/td>~48% WAC<\/td><\/tr>
      Epogen<\/td>Epoetin alfa<\/td>2018<\/td>~51% WAC<\/td><\/tr>
      Lantus<\/td>Insulin glargine<\/td>2021 (Semglee)<\/td>65% WAC at launch<\/td><\/tr>
      Humira<\/td>Adalimumab<\/td>Jan 2023<\/td>5-14% WAC (early; ongoing)<\/td><\/tr>
      Stelara<\/td>Ustekinumab<\/td>2023<\/td>80-90% WAC at launch<\/td><\/tr>
      Avastin<\/td>Bevacizumab<\/td>2019<\/td>Significant (ongoing)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

      Table B: U.S. Biosimilar Supportive Care Adoption Rates<\/h3>\n\n\n\n
      Reference Product<\/th>Biosimilar Penetration (%)<\/th>WAC Reduction vs. Reference<\/th><\/tr><\/thead>
      Filgrastim (Neupogen)<\/td>84.8%<\/td>~55%<\/td><\/tr>
      Epoetin alfa (Epogen\/Procrit)<\/td>76.2%<\/td>~51%<\/td><\/tr>
      Pegfilgrastim (Neulasta)<\/td>52.6%<\/td>~48%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

      Table C: Key Legislative and Regulatory Milestones<\/h3>\n\n\n\n
      Year<\/th>Event<\/th>Patient Impact<\/th><\/tr><\/thead>
      2010<\/td>BPCIA enacted<\/td>Created 351(k) pathway; established 12-year exclusivity<\/td><\/tr>
      2015<\/td>First U.S. biosimilar approved (Zarxio\/filgrastim)<\/td>Opened supportive care biosimilar market<\/td><\/tr>
      2017<\/td>Sandoz v. Amgen (SCOTUS)<\/td>Clarified patent dance participation rules<\/td><\/tr>
      2021<\/td>Semglee approved as interchangeable biosimilar<\/td>First interchangeable insulin biosimilar; 65% WAC discount<\/td><\/tr>
      2022<\/td>Inflation Reduction Act enacted<\/td>Medicare Part D out-of-pocket cap ($2,000 from 2025); drug price negotiation authority; biosimilar void risk created<\/td><\/tr>
      2023<\/td>Adalimumab biosimilars launch in U.S.<\/td>Largest single biosimilar entry event by reference product revenue<\/td><\/tr>
      2023<\/td>Ustekinumab biosimilars launch in U.S.<\/td>80-90% WAC discounts on first entrants<\/td><\/tr>
      2025<\/td>Medicare Part D out-of-pocket cap at $2,000 effective<\/td>Direct reduction in patient financial exposure<\/td><\/tr>
      2026<\/td>First IRA Medicare drug price negotiations in effect<\/td>Pricing uncertainty for high-spend biologics; biosimilar development disincentive risk operative<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

      Table D: Barriers to Patient-Level Biosimilar Savings and Their Levers<\/h3>\n\n\n\n
      Barrier<\/th>Category<\/th>Primary Lever for Resolution<\/th><\/tr><\/thead>
      Interchangeability designation requirement<\/td>Regulatory<\/td>FDA guidance or legislative harmonization<\/td><\/tr>
      Patent thickets \/ BPCIA litigation<\/td>Legal\/IP<\/td>Purple Book patent reform; earlier IPR standing<\/td><\/tr>
      ASP-plus-6 provider incentive<\/td>Reimbursement<\/td>BIOSIM Act or CMS rulemaking<\/td><\/tr>
      PBM rebate preference for originators<\/td>Market structure<\/td>Formulary transparency regulation; rebate pass-through requirements<\/td><\/tr>
      Copay accumulator programs<\/td>Benefit design<\/td>Federal CAAP prohibition legislation<\/td><\/tr>
      Prescriber hesitancy \/ nocebo effect<\/td>Behavioral<\/td>Pre-switch counseling protocols; RWE generation<\/td><\/tr>
      IRA development disincentive<\/td>Policy<\/td>CMS guidance on biosimilar exclusions from negotiation eligibility<\/td><\/tr>
      High biosimilar development cost<\/td>Market<\/td>Shared development programs; NIH manufacturing partnerships<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
      \n\n\n\n

      This analysis is prepared for informational purposes for pharma\/biotech IP teams, portfolio managers, R&D leads, and institutional investors. It does not constitute investment advice. Patent landscapes and regulatory designations change; verify current status through authoritative primary sources including the FDA Purple Book, USPTO patent database, and PTAB docket before making commercial or investment decisions.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

      Executive Summary Biologics account for roughly 2% of U.S. prescriptions but consumed 38-40% of total pharmaceutical spending in 2023. In […]<\/p>\n","protected":false},"author":1,"featured_media":38026,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-23932","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/23932","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=23932"}],"version-history":[{"count":3,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/23932\/revisions"}],"predecessor-version":[{"id":38027,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/23932\/revisions\/38027"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/38026"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=23932"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=23932"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=23932"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}